


Seroconversion rates following COVID-19 vaccination among patients with cancer

Graphical abstract



Authors

Astha Thakkar,
Jesus D. Gonzalez-Lugo,
Niyati Goradia, ..., Lucia Wolgast,
Amit Verma, Balazs Halmos

Correspondence

amit.verma@einsteinmed.org (A.V.),
bahalmos@montefiore.org (B.H.)

In brief

Evaluating the IgG levels against SARS-CoV-2 spike protein, Thakkar et al. demonstrate high rates of seroconversion in a diverse cohort of patients with cancer, while identifying lower immunogenicity in patients with hematologic malignancies and in patients having received immunosuppressive therapies.

Highlights

- COVID-19 vaccines lead to high rates of seroconversion among patients with cancer
- Patients with hematologic malignancies show lower immunogenicity post vaccination
- Prior immunosuppressive therapies lead to lower responsiveness to COVID-19 vaccines
- Prior COVID infection leads to more robust antibody responses to COVID-19 vaccines



Article

Seroconversion rates following COVID-19 vaccination among patients with cancer

Astha Thakkar,¹ Jesus D. Gonzalez-Lugo,¹ Niyati Goradia,¹ Radhika Gali,¹ Lauren C. Shapiro,¹ Kith Pradhan,¹ Shafia Rahman,¹ So Yeon Kim,¹ Brian Ko,¹ R. Alejandro Sica,¹ Noah Kornblum,¹ Lizamarie Bachier-Rodriguez,¹ Margaret McCort,² Sanjay Goel,¹ Roman Perez-Soler,¹ Stuart Packer,¹ Joseph Sparano,¹ Benjamin Gartrell,¹ Della Makower,¹ Yitz D. Goldstein,³ Lucia Wolgast,³ Amit Verma,^{1,*} and Balazs Halmos^{1,4,*}

¹Department of Oncology, Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY 10461, USA

²Department of Medicine, Division of Infectious Diseases, Montefiore Medical Center, Bronx, NY 10461, USA

³Department of Pathology, Montefiore Medical Center, Bronx, NY 10461, USA

⁴Lead contact

*Correspondence: amit.verma@einsteinmed.org (A.V.), bahalmos@montefiore.org (B.H.)

<https://doi.org/10.1016/j.ccell.2021.06.002>

SUMMARY

As COVID-19 adversely affects patients with cancer, prophylactic strategies are critically needed. Using a validated antibody assay against SARS-CoV-2 spike protein, we determined a high seroconversion rate (94%) in 200 patients with cancer in New York City that had received full dosing with one of the FDA-approved COVID-19 vaccines. On comparison with solid tumors (98%), a significantly lower rate of seroconversion was observed in patients with hematologic malignancies (85%), particularly recipients following highly immunosuppressive therapies such as anti-CD20 therapies (70%) and stem cell transplantation (73%). Patients receiving immune checkpoint inhibitor therapy (97%) or hormonal therapies (100%) demonstrated high seroconversion post vaccination. Patients with prior COVID-19 infection demonstrated higher anti-spike IgG titers post vaccination. Relatively lower IgG titers were observed following vaccination with the adenoviral than with mRNA-based vaccines. These data demonstrate generally high immunogenicity of COVID-19 vaccination in oncology patients and identify immunosuppressed cohorts that need novel vaccination or passive immunization strategies.

INTRODUCTION

COVID-19 can result in increased morbidity and mortality in patients with cancer (Kuderer et al., 2020; Mehta et al., 2020; Bakouny et al., 2020), suggesting the need for prophylactic strategies in this immunosuppressed population. In patients with cancer who were affected by COVID-19, increased age, comorbidities, poor performance status, and thoracic and hematologic malignancies have been identified as adverse prognostic indicators for reduced survival (Grivas et al., 2021; Robilotti et al., 2020; Mehta et al., 2020). Follow-up studies on seroconversion in cancer patients with COVID-19 demonstrated that while most will develop antibody response similar to the general population, subgroups of cancer patients with hematologic malignancies, receiving anti-CD20 antibody therapies and stem cell transplantation, exhibit lower rates of seroconversion (Thakkar et al., 2021; Marra et al., 2020). These results suggested that overall high seroconversion rates might be anticipated in patients with malignancies following COVID-19 vaccinations as well, with likely reduced immunogenicity in certain subgroups of patients manifesting from different degrees and mechanisms of immune suppression. Patients with cancer can be immunocompromised due to a multitude of factors, such as the underlying malignancy itself, bone marrow suppressive effects of cytotoxic chemotherapy, and prior or ongoing treatments with a high degree of

immunosuppressive effects, such as corticosteroids, B-cell depleting therapies (i.e., anti-CD20 antibodies), cell therapies (especially chimeric antigen receptor [CAR]-T cell), and stem cell transplantation.

It is critical to understand the immunogenicity of approved vaccines for assessing the need of ongoing social isolation and other strategies to mitigate the risk of contracting COVID-19 by immunosuppressed patients, and for designing and rapidly conducting clinical studies focused on passive immunization strategies and vaccine trials assessing unique schedules to enable boosting of the immune response. However, trials of the currently approved COVID-19 vaccines in general excluded patients with a diagnosis of a malignancy, therefore information on the safety and efficacy of these vaccines regarding the development of effective immunity currently is extremely sparse (Friese et al., 2021). Given the higher morbidity and mortality of patients with cancer and COVID-19, their ongoing need to be exposed to the healthcare system, and their frequent need for immunosuppressive therapies, patients with cancer have been identified as a high-priority subgroup for COVID-19 vaccinations, an effort supported by multiple key organizations (Ribas et al., 2021; Van Der Veldt et al., 2021; Desai et al., 2021).

While patients with cancer clearly represent a highly susceptible group with a strong and immediate need to be protected by available, effective vaccines, there remain many uncertainties.






Figure 1. CONSORT diagram showing the patient cohort

Two hundred and thirteen patients consented to study participation and 29 were enrolled via retrospective chart review. Ultimately based on study criteria, 233 patients were evaluable for vaccine safety analysis and 200 patients were evaluable for vaccine efficacy analysis. One hundred and eighty-five of the 200 patients evaluated for vaccine efficacy analysis were then further assessed as a vaccinated cohort for antibody titer comparisons.

For example, following certain immunosuppressive therapies, such as an autologous or allogeneic stem cell transplantation, anti-CD20 therapies, or T cell-directed regimens, vaccinations have low efficacy and their best timing is unclear (Jaffe et al., 2006; Rubin et al., 2014). Such guidance is also lacking for patients undergoing cytotoxic chemotherapy. One randomized study did not suggest notable differences in influenza vaccine immunogenicity dependent on whether vaccination was given on the day of chemotherapy or during the neutropenic period of the treatment cycle (Keam et al., 2017). While many agencies have suggested administering vaccines 1–2 weeks prior to a chemotherapy dose, this recommendation has not been practical with limited vaccination slot availability, variable chemotherapy (e.g., weekly), and vaccine administration schedules (e.g., two doses of BNT162b2 are recommended to be given 21 days apart while two doses of mRNA-1273 are given 28 days apart), leading to liberal recommendations to allow the most rapid vaccination of these immunosuppressed patients (Desai et al., 2021). Vaccine safety and immunogenicity information is also generally lacking in the context of therapies that stimulate the immune system, such as immune checkpoint inhibitor (ICI) therapy, with a few studies suggesting general safety and possibly heightened immunity in this context (Waissengrin et al., 2021).

To narrow this key knowledge gap, we conducted this study to comprehensively determine the immunogenicity of vaccines in a cohort of patients with a diagnosis of a malignancy in New York City via evaluation of rates of anti-spike immunoglobulin G (IgG) antibody positivity following vaccination with one of the three Food and Drug Administration (FDA)-approved COVID-19 vaccines.

RESULTS

Study cohort

Two hundred and thirteen patients were enrolled in the study via informed-consent process. An additional 29 patients with cancer who underwent SARS-CoV-2 spike IgG testing were identified by retrospective chart review. Eighteen patients did not have a SARS-CoV-2 spike IgG test performed after consenting and were excluded. Another 20 patients were excluded as they had a SARS-CoV-2 spike IgG test before completion of a full vaccination series according to FDA guidance (6 with negative and 14 with positive results). Two more patients were excluded who had a negative SARS-CoV-2 spike IgG and no clear documentation of dates or types of vaccine, and two more patients were excluded due to duplicate medical records. Finally, 233 patients with cancer having completed the FDA-recommended two doses of the mRNA vaccines (BNT162b2 [Polack et al., 2020] or mRNA-1273 [Baden et al., 2020]) or one dose of the adenoviral vaccine (AD26.COVS.2 [Sadoff et al., 2021]) were included in the safety analysis (Figure 1). A cohort of 200 patients underwent a SARS-CoV-2 spike IgG test and was included in the immunogenicity analysis. Serological data (positive or negative IgG test) from these 200 patients was used in association studies between cancer subtypes and treatments. We also investigated the association between the quantitative titer of SARS-CoV-2 spike IgG and cancer subtypes and treatments. One hundred and eighty-five of 200 patients had IgG titers available that were at least 7 days after the last dose of the vaccine (“vaccinated cohort with titers”). Twenty-six de-identified patients without a cancer diagnosis who had completed COVID-19 vaccination and received a SARS-CoV-2 IgG spike antibody test >7 days after

Table 1. Baseline characteristics of the cohort

Characteristic	N	%
Age, median (range)	67 (27–90) years	
Sex		
Male	84	42%
Female	116	58%
Race		
White	43	22%
African American	64	32%
Hispanic	78	39%
Asian	10	5%
Other	5	3%
Type of malignancy		
Solid tumor	134	67%
Hematologic malignancy	66	33%
Malignancy category		
Solid tumor		
Breast	51	26%
Gastrointestinal	27	14%
Genitourinary	18	9%
Gynecologic oncology	10	5%
Thoracic/head & neck	25	13%
Skin/musculoskeletal	2	1%
Carcinoma of unknown primary	1	1%
Hematologic malignancy		
Lymphoid	26	13%
Myeloid	18	9%
Plasma cell	22	11%
Cancer status at the time of vaccine		
Active	110	55%
Progressive	7	4%
Relapse/recurrent	33	17%
Remission	50	25%
Type of vaccine		
BNT162b2	115	58%
mRNA-1273	62	31%
AD26.COVS2.S	20	10%
mRNA (type unknown)	3	2%

their most recent vaccine dose were used as a control cohort (Table S1). This is represented in the CONSORT diagram (Figure 1).

Baseline characteristics

A total of 200 patients who completed their full vaccination schedule according to FDA guidance were included in the efficacy study. The median age of the patient population was 67 years (range 27–90 years). Fifty-eight percent (116/200) of patients were female and 42% (84/200) were male. The ethnicity/race of the patients represented the diverse patient population of the Bronx, New York. Sixty-four patients (32%) identified their ethnicity as African American, 78 (39%) as Hispanic, 40 (22%) as Caucasian, 10 (5%) as Asian, and 5 (3%) as other ethnicities. One

Table 2. Types of cancer therapy in the cohort

Type of cancer treatment	n	%
Antibody-drug conjugate	7	4%
Anti-CD20 antibody therapy	23	12%
Anti-CD38 antibody therapy	10	5%
Anti-HER2 antibody therapy	16	8%
AR-targeted therapy	6	3%
BCL-2 inhibitor	7	4%
BTK inhibitor	2	1%
CAR-T cell therapy	3	2%
CDK4/6 inhibitors	5	3%
Chemotherapy	112	56%
Clinical trial (experimental therapy)	7	4%
EGFR inhibitor	1	1%
Hormonal therapy (ADT, OFS, and AI)	47	24%
Immune checkpoint inhibitor	31	16%
Immunomodulator	22	11%
mTOR inhibitors	2	1%
No treatment	11	6%
Protease inhibitor	19	10%
Radiation	55	28%
Stem cell transplant	26	13%
Supportive care	6	3%
Surgery	59	30%
TGFβ inhibitor	3	2%
Tyrosine kinase inhibitor	9	5%
VEGF inhibitor	7	4%

AR, androgen receptor; BCL-2, B cell lymphoma 2; BTK, Bruton's tyrosine kinase; EGFR, epidermal growth factor receptor; ADT, androgen deprivation therapy; OFS, ovarian function suppression; AI, aromatase inhibitors; mTOR, mammalian target of rapamycin; TGFβ, transforming growth factor β; VEGF, vascular endothelial growth factor.

hundred and thirty-four patients (67%) were diagnosed with a solid tumor while 66 patients (33%) had a hematologic malignancy with a balanced representation of all common cancer types (Table 1). As patients were recruited from our outpatient hematology/oncology clinics, most patients had an active cancer diagnosis. One hundred and fifty patients (75%) had an active malignancy and 135 patients (67%) were in active cancer therapy at the time of their vaccination, with 112 (56%) patients on active chemotherapy. Thirty-eight (19%) patients were on active chemotherapy within 48 h of at least one of the vaccine doses. Types of cancer therapies are listed in detail in Table 2. One hundred and fifteen patients (54%) had completed vaccination with the BNT162b2 vaccine and 62 (31%) with the mRNA-1273 mRNA vaccine, while 20 (10%) had received the single dose of Ad26.COVS2.S vaccine. Three patients had received a complete mRNA vaccination series; however, the information about the type (BNT162b2 versus mRNA-1273) was not available.

Overall immunogenicity and safety of SARS-CoV2 vaccine

The anti-SARS-CoV-2 spike protein antibody test (Abbott) was performed, which demonstrated a high rate of seropositivity




Figure 2. Association of anti-SARS-CoV-2 spike IgG with vaccine types and cancer types

(A) Patients with hematologic malignancies had lowest titers when compared with those with solid tumors and non-cancer patient controls. No difference was seen between patients with solid tumors and controls.

(B) Anti-spike protein IgG antibody titers (AU/mL) were significantly higher in patients who received mRNA vaccines than in those who received adenoviral vaccine.

Box plots here and in subsequent figures show median (horizontal bar), the 75th and 25th quartiles, and error bars depicting the largest and smallest values (up to 1.5 times the interquartile range). Differences assessed by Kruskal-Wallis test.

(94%) with only 13 (6%) patients with a negative value (titer below 50 arbitrary units per milliliter [AU/mL]). Percent positivity appeared similarly between the vaccine types (BNT162b2 95%, mRNA-1273 94%, and Ad26.COVS.S 85%), with a trend toward lesser positivity with the Ad26.COVS.S vaccine. We also assessed antibody titers in a subcohort of 185 patients with available IgG levels >7 days after final dose of vaccine (vaccinated cohort matching the definition of our non-cancer control cohort). The median time between spike antibody test and vaccine dose for this subcohort is 30 days (interquartile range 19–53 days). In solid malignancy patients the median was 31.5 days, and in patients with hematologic malignancies the median was 28.5 days.

Highest IgG titers were seen with the mRNA-1273 vaccine (median 11,963 AU/mL, standard deviation [SD] 18,742), followed by the BNT162b2 vaccine (median 5,173 AU/mL, SD 16,699) and the single-dose Ad26.COVS.S vaccine (median 1,121 AU/mL, SD 17,571) ($p < 0.05$, Kruskal-Wallis test, Figure 2B). Recognizing that the Ad26.COVS.S vaccine was introduced late onto the market, which might or might not account for the lower titers of spike antibodies, we assessed associations of antibody seropositivity and antibody titers with time from completion of vaccination. While there was no association with titer levels, we found a statistically significant positive association between the time from vaccination until IgG testing and antibody seropositivity ($p = 0.03$, Kruskal-Wallis test). We then conducted a multivariate analysis with a generalized linear model and observed that the relationship between vaccine type and titers remained significant after accounting for the effect of time from vaccine (Figure S1).

Vaccinations appeared to be generally very safe in this cohort, with mostly mild and moderate anticipated adverse effects reported. In the safety analysis, 139 patients had received BNT162b2 first dose, 131 patients BNT162b2 second dose, 71 patients mRNA-1273 first dose, 64 patients mRNA-1273 second dose, and 23 patients the single-dose Ad26.COVS.S vaccine. Across all the doses, 194 vaccination episodes were reported to lead to no adverse effects overall. Sore arm and muscle aches were the first and second most common reported adverse effects in 131 and 49 instances, respectively. A comprehensive analysis of adverse effect profile of each type of vaccine is presented in Figures S4 and S5.

Solid tumors versus hematologic malignancies

In the cohort of patients with solid tumors, seropositivity post vaccination was high (98%), while a significantly lower seropositivity rate was seen in patients with hematologic malignancies (85%, $p = 0.001$, Fisher's exact test). Analysis of the subcohort of 185 patients with available IgG titers >7 days post vaccination revealed significantly higher titer values in solid tumors (median 7,858 AU/mL, SD 18,103) than hematologic malignancies (median 2,528 AU/mL, SD 12,338, $p = 0.013$, Kruskal-Wallis test). Furthermore, to ensure that the difference in titers was not confounded by different time intervals from vaccination, we conducted a multivariate analysis using time from vaccination to IgG assay testing as a confounder and determined that lower titers in hematologic malignancies than in solid tumors were still significant ($p = 0.0012$). Comparison of titers from non-cancer controls (Table S1) revealed no significant difference when compared with solid-tumor patients but showed a statistically significant




Figure 3. Association of anti-SARS-CoV-2 spike IgG with therapy

(A–C) Anti-spike protein IgG antibody titers (AU/mL) after full vaccination did not significantly differ in patients receiving active therapy (A), chemotherapy (B), or radiation therapy (C) when compared with respective counterparts.

(D) Patients that had received surgery versus no surgery had no significant difference in titer levels ($p = 0.08$).

Box plots are shown with differences assessed by Kruskal-Wallis test.

difference when compared with patients with hematologic malignancy ($p = 0.01$, Kruskal-Wallis test) (Figure 2A).

Association with active cancer therapies and immunosuppressive therapies

No significant differences in seroconversion were seen when comparing patients on active cancer therapy with patients who were not (96% versus 93%). However, significantly lower rates of seropositivity were seen in patients on active cytotoxic chemotherapy (92%) versus others (99%, $p = 0.04$) without notable differences in titer levels (Figure 3). Next, we focused our analysis on patients who had received specific immunosuppressive therapies, such as stem cell transplantation, anti-CD20 therapy, or CAR-T cell therapy. We observed significantly lower seroconversion rates in patients who underwent these therapies: stem cell transplant (73%, $p = 0.0002$, Fisher's exact test), anti-CD20 therapies (70%, $p = 0.0001$, Fisher's exact test) and CAR-T

cell treatments (all three patients remained seronegative after vaccination, $p = 0.0002$, Fisher's exact test) (Table 3). Of the 26 stem cell transplant patients, 23 received an autologous and 3 an allogeneic transplant (2 seropositive, 1 seronegative). Accordingly, significantly lower titer levels were also seen in patients receiving anti-CD20 therapies compared with the overall group of patients (Figure 4). These results highlighted the continued susceptibility of patients receiving these therapies during the pandemic.

Associations with other patient demographics and treatments

These analyses are available in Table S2.

Age

Our patient population had a wide age range (27–90 years). We studied the association between age and SARS-CoV-2 IgG spike antibody seroconversion rates and observed no statistically

Table 3. Association of anti-spike IgG with disease characteristics

Type of malignancy	Positive anti-SARS-CoV-2 spike IgG patients, n (%)	Negative anti-SARS-CoV-2 spike IgG patients, n (%)	p value
Solid malignancy	131 (98%)	3 (2%)	0.001053*
Hematologic malignancy	56 (85%)	10 (15%)	
Type of cancer therapy			
Anti-CD20	16 (70%)	7 (30%)	0.0001168**
Stem cell transplant	19 (73%)	7 (27%)	0.0002866**
CAR-T cell therapy	0 (0%)	3 (100%)	0.0002178**
Hormonal therapy	47 (100%)	0 (0%)	0.04129**
Immune checkpoint inhibitor therapy	30 (97%)	1 (3%)	0.6962

*Statistically significant when compared with each other.

**Statistically significant when compared with overall cohort.

significant association between these variables ($p = 0.13$, Kruskal-Wallis test).

Ethnicity

Given the ethnically diverse cohort in this study, we studied the association between seropositivity and patient ethnicity. We observed that there was no statistically significant association between ethnicity and spike antibody seroconversion rates ($p = 0.4574$, Fisher's exact test).

Time since immunosuppressive therapy

We also studied the association between time since specific immunosuppressive therapies and immunogenicity. We divided patients into two groups: <365 days and >365 days since anti-CD20 antibody therapy or stem cell transplant and anti-SARS-CoV-2 spike IgG testing. The comparison between seropositivity and time since immunosuppressive treatment was not statistically significant ($p = 1$, Fisher's exact test).

Steroid use

Our cohort included 55 patients who had used steroids (daily or occasional) at the time of vaccination. Five had a negative spike IgG result and 50 had positive results. This was not statistically different from the entire cohort ($p = 0.348$, Fisher's exact test).

Treatment within 48 h of a vaccine dose

We collected data to evaluate whether patients who received active cancer therapies 48 h before or after a vaccine dose had lesser seropositivity rates. Thirty-eight patients met the above criteria. We observed that three patients were seronegative, and there was no statistically significant association regarding whether patients received cancer therapies within 48 h of the vaccine or not ($p = 0.7$, Fisher's exact test). These patients were compared with the entire cohort. These analyses are available in [Table S2](#).

Association with additional cancer therapies

We observed high rates of post-vaccination seroconversion in patients on hormonal therapy (100% seropositivity, $p = 0.04$) and ICI therapy (97%, $p = 0.69$, Fisher's exact test) when compared with the rest of the cohort. Interestingly, while all patients on CDK4/6 inhibitor treatment showed positive anti-spike IgG test results, notably antibody titers were very low in this small subset ($n = 5$, median 1,242 AU/mL SD 2,435 versus median 6,887 AU/mL, SD 17,843 for overall cohort) ([Figure 5](#)). Given the known involvement of the CDK4/6 pathway in immune activation ([Chen-Kiang, 2003](#); [Cingöz and Goff, 2018](#); [Laphanuwat and Jirawatnotai, 2019](#)), this might be biologically plausible

and warrants further studies into the impact of CDK4/6 inhibitor on vaccine efficacy. We also noted trends toward lower titers among other subgroups, such as patients having received BCL2- or BTK-targeted therapy, consistent with prior observations on their negative impact on vaccine efficacy ([Pleyer et al., 2021](#)) ([Figure S3](#)).

Association with prior COVID-19

Previous studies have reported heightened antibody responses to COVID-19 vaccinations in patients with a prior COVID-19 infection ([Krammer et al., 2021](#)). Our cohort included 22 patients with cancer who had known prior COVID-19, and a high rate of seroconversion was seen in this subset (21/22 seroconverted for a 95% seroconversion rate with one patient not seroconverting having received an autologous stem cell transplant). Antibody titers in previously infected patients were significantly higher than those who were not known to be previously infected (prior COVID-19: median 46,737 AU/mL, SD 18,681; others: median 5,296 AU/mL, SD 16,193, $p < 0.001$, Kruskal-Wallis test) ([Figure 5D](#)).

DISCUSSION

COVID-19 disease has had a devastating impact worldwide and especially so among patients with a cancer diagnosis. Various factors adversely affect outcomes in cancer patients affected with COVID-19, including impact of underlying disease on performance status, age/comorbidities of affected patients, immune suppression related to disease such as in patients with hematologic malignancies, and immune-suppressive effects of disease-directed therapies ([Lee et al., 2020a, 2020b](#); [Jee et al., 2020](#); [García-Suárez et al., 2020](#); [Mehta et al., 2020](#); [Westblade et al., 2020](#)). In addition, patients with cancer requiring active therapy face frequent exposure to the healthcare system, increasing the risk of acquiring COVID-19. Lastly, treatment modifications due to the ongoing pandemic can compromise disease outcomes, amplifying the urgent need to implement widespread vaccination of patients with malignant disease—an initiative with broad support from a large swath of cancer care/advocacy organizations.

While all three FDA-approved vaccines, the mRNA-based mRNA-1273 (Moderna) and BNT162b2 (Pfizer/BioNTech) and the adenovirus-based Ad26.COV2.S (Johnson & Johnson), yield




Figure 4. Association of anti-SARS-CoV-2 spike IgG with immunosuppressive therapies

(A and B) Anti-spike protein IgG antibody titers (AU/mL) after full vaccination did not significantly differ in patients having received stem cell transplantation (SCT) (A) or anti-CD38 antibody therapy (B) when compared with respective counterparts.

(C and D) Patients receiving anti-CD20 antibody treatments (C) or CAR-T cell therapy (D) had a significantly lower titer after vaccination when compared with respective counterparts.

Box plots are shown with differences assessed by Kruskal-Wallis test.

a high level of protection against the current circulating variants in the general population, limited data regarding their immunogenicity among patients with a cancer diagnosis are available. Recent studies from the United Kingdom and France have reported lower seroconversion rates following a single dose of mRNA vaccination (Monin-Aldama et al., 2021, Barrière et al., 2021). Lower seropositivity rates have also been observed in patients with chronic lymphocytic leukemia and myeloma (Herishanu et al., 2021; Terpos et al., 2021; Bird et al., 2021) and in those undergoing therapy with BTK inhibitors or venetoclax/anti-CD20 therapy, in line with our observations (Herishanu et al., 2021). These early studies clearly highlight the need to complete full vaccination schedules for optimum seroconversion and also emphasize the need for larger cohort studies to determine the immunogenicity of COVID-19 vaccines among patients receiving distinct cancer therapeutics.

Several shortcomings of our study need to be listed. These include limited representation of some patient cohorts not allowing clear conclusions regarding seroconversion rates among less common malignancy types or less frequently used treatment approaches. Our cohort also over-represented patients on active therapy, as recruitment occurred over a short period in our outpatient departments. In addition, our study relies solely on the anti-spike protein IgG levels as a surrogate for immunity to COVID-19. Admittedly, the anti-spike IgG antibody used in our study, albeit specific to the receptor binding domain of the spike protein, might still not necessarily correlate with virus-neutralizing activity. Our study also did not evaluate the level of SARS-CoV-2-specific T cell responses. Further research will be needed to directly assess virus neutralization and cellular immunity (Bange et al., 2021). Another potential limitation is underestimation of titer values for anti-spike antibodies, as evidence




Figure 5. Association of anti-SARS-CoV-2 spike IgG with type of therapy and prior COVID-19 history

(A) Anti-spike protein IgG antibody titers (AU/mL) after full vaccination did not significantly differ in patients receiving immune checkpoint inhibitor (ICI) therapy when compared with those who did not.

(B) Patients receiving hormonal therapy had a significantly higher titer after vaccination.

(C) Patients receiving CDK4/6 inhibitor therapy had a significantly lower titer after vaccination.

(D) Patients with prior COVID-19 infection had significantly higher IgG titers.

Box plots are shown with differences assessed by Kruskal-Wallis test.

suggests that titers may rise over time, and the upper limit of detection of our assay is 50,000 AU/mL (Widge et al., 2020); however, a cutoff of 7 days was used to match the control cohort and eliminate bias in the analysis. Lastly, some observations are based on smaller subsets and post hoc analyses, so that larger studies are needed for validation.

Our study, along with other emerging data, strongly highlights the continued need to vaccinate patients with a cancer diagnosis urgently and broadly, as vaccinations are likely to be highly effective. On the other hand, our study highlights at-risk cohorts of patients, in particular patients with hematologic malignancies following receipt of immunosuppressive therapies such as stem cell transplantation, anti-CD20 therapies, and CAR-T cell treatments. These cohorts of patients could potentially benefit from passive immunization with anti-COVID anti-

bodies in the face of the ongoing pandemic. In fact, monoclonal anti-COVID-19 antibodies have shown therapeutic and prophylactic potential in transplant or at-risk patient cohorts (Rizk et al., 2021; Hurt and Wheatley, 2021; Dhand et al., 2021). In addition, higher doses or booster doses of some vaccines or vaccinations of mixed vaccine types might offer stronger immunogenicity and need to be explored in immunosuppressed patients. Lastly, protective measures such as masking and social distancing will remain logical aspects of defensive management strategies for highly immune-suppressed patients during the pandemic until safe herd immunity levels of population-level vaccinations are reached.

In summary, we present a large cohort of patients with malignancy who underwent full COVID-19 vaccination according to FDA guidance. In this cohort of ethnically diverse patients with

broad representation of a wide range of malignancies and therapies, very high seropositivity rates were observed, in contrast to previously published smaller cohort studies focusing on unique subsets of susceptible patients or non-standard vaccination schedules. Statistically significantly lower seropositivity rates were observed in patients with hematologic malignancies and patients having received immunosuppressive therapies. Our findings support broad and urgent COVID-19 vaccinations in patients with a cancer diagnosis to enable optimal cancer treatment delivery during the ongoing COVID-19 pandemic.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
 - Lead contact
 - Materials availability
 - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
 - Patient data collection
- METHOD DETAILS
 - Anti-SARS-CoV-2 spike IgG assay
- QUANTIFICATION AND STATISTICAL ANALYSIS

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at <https://doi.org/10.1016/j.ccell.2021.06.002>.

ACKNOWLEDGMENTS

We acknowledge Albert Einstein Cancer Center grant P30 CA013330 and NCORP grant 2UG1CA189859-06 in providing funding for this project. This work was supported partly by the Jane A. and Myles P. Dempsey fund.

AUTHOR CONTRIBUTIONS

A.T., A.V., and B.H. conceived and managed the study; J.D.G.-L., N.G., R.G., L.C.S., S.R., S.Y.K., B.K., R.A.S., N.K., L.B.-R., M.M., S.G., J.S., B.G., and D.M. participated in patient recruitment and data curation; K.P. oversaw data analyses; S.P. and R.P.-S. contributed to project administration; Y.D.G. and L.W. oversaw investigations. All authors contributed to writing the manuscript.

DECLARATION OF INTERESTS

A.V. has received research funding from GlaxoSmithKline, BMS, Janssen, Incyte, MedPacto, Celgene, Novartis, Curis, Prelude, and Eli Lilly and Company, has received compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene, and has equity ownership in Stelexis Therapeutics. All other authors declare no competing interests.

Received: May 6, 2021

Revised: May 26, 2021

Accepted: June 2, 2021

Published: August 9, 2021

REFERENCES

Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S.A., Rouphael, N., Creech, C.B., et al. (2020). Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N. Engl. J. Med.* **384**, 403–416.

Bakouny, Z., Hawley, J.E., Choueiri, T.K., Peters, S., Rini, B.I., Warner, J.L., and Painter, C.A. (2020). COVID-19 and cancer: current challenges and perspectives. *Cancer Cell* **38**, 629–646.

Bange, E.M., Han, N.A., Wileyto, P., Kim, J.Y., Gouma, S., Robinson, J., Greenplate, A.R., Hwee, M.A., Porterfield, F., Owoyemi, O., et al. (2021). CD8⁺ T cells contribute to survival in patients with COVID-19 and hematologic cancer. *Nat. Med.* <https://doi.org/10.1038/s41591-021-01386-7>.

Barrière, J., Chamorey, E., Adjtoutah, Z., Castelnaud, O., Mahamat, A., Marco, S., Petit, E., Leysalle, A., Raimondi, V., and Carles, M. (2021). Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. *Ann. Oncol.* <https://doi.org/10.1016/j.annonc.2021.04.019>.

Bird, S., Panopoulou, A., Shea, R.L., Tsui, M., Saso, R., Sud, A., West, S., Smith, K., Barwood, J., Kaczmarek, E., et al. (2021). Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma. *Lancet Haematol.* **8**, e389–e392.

Bradley, B.T., Bryan, A., Fink, S.L., Goecker, E.A., Roychoudhury, P., Huang, M.-L., Zhu, H., Chaudhary, A., Madarampalli, B., Lu, J.Y.C., et al. (2021). Anti-SARS-CoV-2 antibody levels are concordant across multiple platforms but are not fully predictive of sterilizing immunity. *medRxiv.* <https://doi.org/10.1101/2021.04.26.21256118>.

Chen-Kiang, S. (2003). Cell-cycle control of plasma cell differentiation and tumorigenesis. *Immunol. Rev.* **194**, 39–47.

Cingöz, O., and Goff, S.P. (2018). Cyclin-dependent kinase activity is required for type I interferon production. *Proc. Natl. Acad. Sci.* **115**, E2950–E2959.

Desai, A., Gainor, J.F., Hegde, A., Schram, A.M., Curigliano, G., Pal, S., Liu, S.V., Halmos, B., Groisberg, R., Grande, E., et al. (2021). COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. *Nat. Rev. Clin. Oncol.* **18**, 313–319.

Dhand, A., Lobo, S.A., Wolfe, K., Feola, N., and Nabors, C. (2021). Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: early single-center experience. *Clin. Transplant.* **35**, e14245.

Friese, C.R., Choueiri, T.K., Duma, N., Farmakiotis, D., Grivas, P., Rini, B.I., Shah, D.P., Thompson, M.A., Pergam, S.A., Mishra, S., and Warner, J.L. (2021). Care without a compass: including patients with cancer in COVID-19 studies. *Cancer Cell.* <https://doi.org/10.1016/j.ccell.2021.04.006>.

García-Suárez, J., De La Cruz, J., Cedillo, Á., Llamas, P., Duarte, R., Jiménez-Yuste, V., Hernández-Rivas, J.Á., Gil-Manso, R., Kwon, M., Sánchez-Godoy, P., et al. (2020). Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. *J. Hematol. Oncol.* **13**, 133.

Grivas, P., Khaki, A.R., Wise-Draper, T.M., French, B., Hennessy, C., Hsu, C.Y., Shyr, Y., Li, X., Choueiri, T.K., Painter, C.A., et al. (2021). Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. *Ann. Oncol.* **32**, 787–800.

Herishanu, Y., Avivi, I., Aharon, A., Shefer, G., Levi, S., Bronstein, Y., Morales Moshishvili, M., Ziv-Baran, T., Shorer, Y., Scarfo, L., et al. (2021). Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. *Blood.* <https://doi.org/10.1182/blood.2021011568>.

Hurt, A.C., and Wheatley, A.K. (2021). Neutralizing antibody therapeutics for COVID-19. *Viruses* **13**, 628.

Jaffe, D., Papadopoulos, E.B., Young, J.W., O'reilly, R., J., Prockop, S., Kernan, N.A., Jakubowski, A., Boulad, F., Perales, M.A., Castro-Malaspina, H., and Small, T.N. (2006). Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. *Blood* **108**, 2470–2475.

Jee, J., Foote, M.B., Lumish, M., Stonestrom, A.J., Wills, B., Narendra, V., Avutu, V., Murciano-Goroff, Y.R., Chan, J.E., Derkach, A., et al. (2020). Chemotherapy and COVID-19 outcomes in patients with cancer. *J. Clin. Oncol.* **38**, 3538–3546.

Keam, B., Kim, M.K., Choi, Y., Choi, S.J., Choe, P.G., Lee, K.H., Kim, T.M., Kim, T.Y., Oh, D.Y., Kim, D.W., et al. (2017). Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles. *Cancer* **123**, 841–848.

- Krammer, F., Srivastava, K., Alshammary, H., Amoako, A.A., Awawda, M.H., Beach, K.F., Bermúdez-González, M.C., Bielak, D.A., Carreño, J.M., Chernet, R.L., et al. (2021). Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. *N. Engl. J. Med.* **384**, 1372–1374.
- Kuderer, N.M., Choueiri, T.K., Shah, D.P., Shyr, Y., Rubinstein, S.M., Rivera, D.R., Shete, S., Hsu, C.-Y., Desai, A., De Lima Lopes, G., et al. (2020). Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. *The Lancet* **395**, 1907–1918.
- Laphanuwat, P., and Jirawatnotai, S. (2019). Immunomodulatory roles of cell cycle regulators. *Front. Cell. Dev. Biol.* **7**, 23.
- Lee, L.Y., Cazier, J.-B., Angelis, V., Arnold, R., Bisht, V., Campton, N.A., Chackathayil, J., Cheng, V.W., Curley, H.M., Fittall, M.W., et al. (2020a). COVID-19 mortality in patients with cancer on chemotherapy or other anti-cancer treatments: a prospective cohort study. *Lancet* **395**, 1919–1926.
- Lee, L.Y.W., Cazier, J.-B., Starkey, T., Briggs, S.E.W., Arnold, R., Bisht, V., Booth, S., Campton, N.A., Cheng, V.W.T., Collins, G., et al. (2020b). COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. *Lancet Oncol.* **21**, 1309–1316.
- Marra, A., Generali, D., Zagami, P., Cervoni, V., Gandini, S., Venturini, S., Morganti, S., Passerini, R., Orecchia, R., and Curigliano, G. (2020). Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2. *Ann. Oncol.* **32**, 113–119.
- Mehta, V., Goel, S., Kabarriti, R., Cole, D., Goldfinger, M., Acuna-Villaorduna, A., Pradhan, K., Thota, R., Reissman, S., Sparano, J.A., et al. (2020). Case fatality rate of cancer patients with COVID-19 in a New York hospital system. *Cancer Discov.* **10**, 935–941.
- Monin-Aldama, L., Laing, A.G., Muñoz-Ruiz, M., Mckenzie, D.R., Del Molino Del Barrio, I., Alaguthurai, T., Domingo-Vila, C., Hayday, T.S., Graham, C., Seow, J., et al. (2021). Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority guidelines. *medRxiv*. <https://doi.org/10.1101/2021.03.17.21253131>.
- Pillay, T.S. (2020). Gene of the month: the 2019-nCoV/SARS-CoV-2 novel coronavirus spike protein. *J. Clin. Pathol.* **73**, 366–369.
- Pleyer, C., Ali, M.A., Cohen, J.I., Tian, X., Soto, S., Ahn, I.E., Gaglione, E.M., Nierman, P., Marti, G.E., Hesdorffer, C., et al. (2021). Effect of Bruton tyrosine kinase inhibitor on efficacy of adjuvanted recombinant hepatitis B and zoster vaccines. *Blood* **137**, 185–189.
- Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J.L., Pérez Marc, G., Moreira, E.D., Zerbini, C., et al. (2020). Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. *N. Engl. J. Med.* **383**, 2603–2615.
- Ribas, A., Sengupta, R., Locke, T., Zaidi, S.K., Campbell, K.M., Carethers, J.M., Jaffee, E.M., Wherry, E.J., Soria, J.C., and D'souza, G. (2021). Priority COVID-19 vaccination for patients with cancer while vaccine supply is limited. *Cancer Discov.* **11**, 233–236.
- Rizk, J.G., Forthal, D.N., Kalantar-Zadeh, K., Mehra, M.R., Lavie, C.J., Rizk, Y., Pfeiffer, J.P., and Lewin, J.C. (2021). Expanded access programs, compassionate drug use, and emergency use authorizations during the COVID-19 pandemic. *Drug Discov. Today* **26**, 593–603.
- Robilotti, E.V., Babady, N.E., Mead, P.A., Rolling, T., Perez-Johnston, R., Bernardes, M., Bogler, Y., Caldararo, M., Figueroa, C.J., Glickman, M.S., et al. (2020). Determinants of COVID-19 disease severity in patients with cancer. *Nat. Med.* **26**, 1218–1223.
- Rubin, L.G., Levin, M.J., Ljungman, P., Davies, E.G., Avery, R., Tomblyn, M., Bousvaros, A., Dhanireddy, S., Sung, L., Keyserling, H., and Kang, I. (2014). 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin. Infect. Dis.* **58**, 309–318.
- Sadoff, J., Gray, G., Vandebosch, A., Cárdenas, V., Shukarev, G., Grinsztejn, B., Goepfert, P.A., Truyers, C., Fennema, H., Spiessens, B., et al. (2021). Safety and efficacy of single-dose Ad26.COV2.S vaccine against covid-19. *N. Engl. J. Med.* <https://doi.org/10.1056/NEJMoa2101544>.
- Terpos, E., Trougakos, I.P., Gavriatopoulou, M., Papassotiriou, I., Sklirou, A.D., Ntanasis-Stathopoulos, I., Papanagnou, E.D., Fotiou, D., Kastritis, E., and Dimopoulos, M.A. (2021). Low neutralizing antibody responses against SARS-CoV-2 in elderly myeloma patients after the first BNT162b2 vaccine dose. *Blood*. <https://doi.org/10.1182/blood.2021011904>.
- Thakkar, A., Pradhan, K., Jindal, S., Cui, Z., Rockwell, B., Shah, A.P., Packer, S., Sica, R.A., Sparano, J., Goldstein, D.Y., et al. (2021). Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy. *Nat. Cancer* **2**, 392–399.
- Van Der Veldt, A.A.M., Oosting, S.F., Dingemans, A.C., Fehrmann, R.S.N., Geurtsvankessel, C., Jalving, M., Rimmelzwaan, G.F., Kvistborg, P., Blank, C.U., Smit, E.F., et al. (2021). COVID-19 vaccination: the VOICE for patients with cancer. *Nat. Med.* **27**, 568–569.
- Waissengrin, B., Agbarya, A., Safadi, E., Padova, H., and Wolf, I. (2021). Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. *Lancet Oncol.* **22**, 581–583.
- Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., et al. (2020). SARS-CoV-2 viral load predicts mortality in patients with and without cancer who are hospitalized with COVID-19. *Cancer Cell* **38**, 661–671.e2.
- Widge, A.T., Roupael, N.G., Jackson, L.A., Anderson, E.J., Roberts, P.C., Makhene, M., Chappell, J.D., Denison, M.R., Stevens, L.J., Pruijssers, A.J., et al. (2020). Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. *N. Engl. J. Med.* **384**, 80–82.
- Yang, J., Petitjean, S.J.L., Koehler, M., Zhang, Q., Dumitru, A.C., Chen, W., Derclaye, S., Vincent, S.P., Soumillon, P., and Alsteens, D. (2020). Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor. *Nat. Commun.* **11**, 4541.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
None	Not applicable	Not applicable
Bacterial and virus strains		
None	Not applicable	Not applicable
Biological samples		
Serum sample	Patients recruited in this study	In this study
Chemicals, peptides, and recombinant proteins		
None	Not applicable	Not applicable
Critical commercial assays		
AdviseDx SARS-CoV-2 IgG II assay	Abbott	Please provide the catalog number from Abbott
Deposited data		
Computer code	GitHub	https://github.com/kith-pradhan/CovidVaccineReport/blob/main/report.R
Experimental models: Cell lines		
None	Not applicable	Not applicable
Experimental models: Organisms/strains		
None	Not applicable	Not applicable
Oligonucleotides		
None	Not applicable	Not applicable
Recombinant DNA		
None	Not applicable	Not applicable
Software and algorithms		
R 3.6.2	https://www.r-project.org/	https://www.r-project.org/
Other		
Clinical data	Electronic medical record	Medical record number

RESOURCE AVAILABILITY

Lead contact

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Balazs Halmos, bahalmos@montefiore.org.

Materials availability

This study did not generate new unique reagents.

Data and code availability

The published article includes all data generated and analyzed during this study. Data will be made available freely from the corresponding authors upon request. The utilized computer code has been deposited in GitHub (<https://github.com/kith-pradhan/CovidVaccineReport/blob/main/report.R>). All analyses were conducted with built-in and freely available R packages.

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Patient data collection

The study was approved by the Montefiore-Einstein Institutional Review Board. This study was designed as a cross-sectional cohort study and enrolled subjects being seen in the outpatient practices of the Montefiore/Einstein Cancer Center during April

2021. Participants were enrolled in the study after signing informed consent. Subjects underwent anti-SARS-CoV-2 spike IgG assay, completed a questionnaire focusing on details and adverse effects of COVID-19 vaccination and provided optional consent for future biobanking for research. The protocol also allowed data collection via retrospective chart review for a small number of patients who underwent anti-SARS-CoV-2 spike IgG antibody testing after vaccination as ordered at the discretion of their oncologist. Safety data for vaccines for patients recruited via informed consent was collected via questionnaires with an optional telephone call if patients did not remember dates of the vaccine. Assessment was done at the time when patients signed the informed consent. Safety data for patients recruited via retrospective chart review was collected if data was available as part of electronic medical record. Data for cancer-directed therapy was retrieved from retrospective chart review and strict criteria were used to classify them (e.g., hormonal therapy strictly included androgen deprivation, ovarian function suppression and aromatase inhibitors. Steroids were not considered a part of hormonal therapy). Active cancer means patient with an initial cancer diagnosis on treatment including surgery, radiation, neoadjuvant, adjuvant or systemic chemotherapy or maintenance therapy (ex- lenalidomide for myeloma or immunotherapy maintenance for non-small cell lung cancer) or not on treatment and under active surveillance. Remission means patient with cancer diagnosis in the past who has completed cancer-directed therapy and is now only undergoing surveillance. Relapse/recurrent means patient with cancer diagnosis who had completed cancer-directed therapy and achieved remission or was on maintenance therapy now experiencing disease that needs additional treatment. Progressive means patient with cancer diagnosis who developed disease progression while on systemic therapy.

METHOD DETAILS

Anti-SARS-CoV-2 spike IgG assay

The AdviseDx SARS-CoV-2 IgG II assay was used for the assessment of anti-spike IgG antibody testing. AdviseDx is an automated, two-step chemiluminescent immunoassay performed on the Abbott i2000SR instrument. The assay is designed to detect IgG antibodies directed against the receptor binding domain (RBD) of the S1 subunit of the spike protein of SARS-CoV-2. The RBD is a portion of the S1 subunit of the viral spike protein and has a high affinity for the angiotensin converting enzyme 2 (ACE2) receptor on the cellular membrane (Pillay, 2020; Yang et al., 2020).

The procedure, in brief, is as follows. Patient serum containing IgG antibodies directed against the RBD is bound to microparticles coated with SARS-CoV-2 antigen. The mixture is then washed of unbound IgG and anti-human IgG, acridinium-labeled, secondary antibody is added and incubated. Following another wash, sodium hydroxide is added and the acridinium undergoes an oxidative reaction which releases light energy which is detected by the instrument and expressed as relative light units (RLU). There is a direct relationship between the amount of anti-spike IgG antibody and the RLU detected by the system optics. The RLU values are fit to a logistic curve which was used to calibrate the instrument and expresses results as a concentration in AU/mL (arbitrary units/milliliter). This assay recently has shown high sensitivity (100%) and positive percent agreement with other platforms including a surrogate neutralization assay (Bradley et al., 2021) and also demonstrated high specificity both in the post COVID-19 infection and post vaccination settings. The cutoff value for this assay is 50 AU/mL with <50 AU/ml values reported as negative and the maximum value is 50000 AU/mL.

QUANTIFICATION AND STATISTICAL ANALYSIS

Association between two categorical variables was tested with a Fisher exact test. Association between one categorical and one ordinal variable was tested with a Kruskal-Wallis Rank Sum test. Pre-specified hypotheses to be tested included assessing correlation of seropositivity with solid and hematologic malignancies and between the overall cohort and highly immunosuppressive therapies. All analyses were done in R (version 3.6.2).

Supplemental information

**Seroconversion rates following COVID-19
vaccination among patients with cancer**


Astha Thakkar, Jesus D. Gonzalez-Lugo, Niyati Goradia, Radhika Gali, Lauren C. Shapiro, Kith Pradhan, Shafia Rahman, So Yeon Kim, Brian Ko, R. Alejandro Sica, Noah Kornblum, Lizamarie Bachier-Rodriguez, Margaret McCort, Sanjay Goel, Roman Perez-Soler, Stuart Packer, Joseph Sparano, Benjamin Gartrell, Della Makower, Yitz D. Goldstein, Lucia Wolgast, Amit Verma, and Balazs Halmos

Supplementary Table 1: Characteristics of control cohort. Related to Table 1.

	Baseline characteristics of controls
Age (Median(Range))	64 (37-82) years
Range	37-82 years
Sex	
Male	10 (38%)
Female	16 (62%)
Prior history of COVID	5 (19%)

**Supplementary Table 2: Comparison of SARS-CoV-2 IgG spike with different variables.
Related to Table 3**


	Negative anti-SARS-CoV-2 spike IgG	Positive anti-SARS-CoV-2 spike IgG	<i>p</i> value
<i>Race</i>			
White	3	40	0.4574
Hispanic	5	73	
African American	3	61	
Asian	1	9	
Other	1	4	
<i>Time since transplant</i>			
Transplant < 365 days	1	2	1
Transplant >365 days	6	17	
<i>Time since anti-CD20</i>			
Anti-CD20 exposure <365 days	1	4	1
Anti-CD20 exposure > 365 days	6	12	
<i>Chemo within 48 hours</i>			
Yes	3	35	0.7
IgG seroconversion rate vs age			0.13




Supplementary figure 1: Multivariate analysis between type of vaccine and titer controlling for time since vaccination. Related to Figure 2.

Scatter plot showing relationship between SARS-CoV-2 IgG titer and time since vaccine for different types of vaccine. The relationship between vaccine type and titers remains significant even after accounting for the effect of time to vaccine as shown in multivariate analysis with the *p* values being 0.00682 and 0.00278 for BNT162b2 and mRNA 1273 vaccines, respectively.

A




B




Supplementary Figure 2.: Association of anti-SARS-CoV2 spike IgG with Anti-HER2 and Immunomodulator Therapies. Related to figure 3, 4 and 5.

Spike protein antibody titers after full vaccination did not significantly differ in patients receiving active therapy (A), anti-HER2 therapy (B) or immunomodulators. Differences assessed by Kruskal Wallis Test. Box plots showing median (horizontal bar), the 75th and 25th quartiles and the error bars depicting the largest and smallest values (up to 1.5 times the interquartile range).



Supplementary Figure 3.: Association of anti-SARS-CoV2 Spike IgG with BTK inhibitor and BCL2 inhibitor Therapies. Related to figure 3, 4 and 5.

Spike protein antibody titers after full vaccination were significantly lower in patients who had received (A) BTK inhibitors (B) or BCL-2 inhibitors. Differences assessed by Kruskal Wallis Test. Box plots showing median (horizontal bar), the 75th and 25th quartiles and the error bars depicting the largest and smallest values (up to 1.5 times the interquartile range).



Supplementary Figure 4: Adverse effects following COVID-19 vaccination. Related to Table 1.

A. Frequency of adverse effects from BNT162b2 dose 1.


B. Frequency of adverse effects from BNT152b2 dose 2.

C. Frequency of adverse effects from mRNA 1273 dose 1.

D. Frequency of adverse effects from mRNA 1273 dose 2.

E. Frequency of adverse effects from Ad26.COVS.S.

X axis shows class of adverse event reported, Y axis represents percentage of patients.



Supplementary Figure 5: Severity of vaccine adverse effects. Related to Table 1.

A. Severity of adverse effects from BNT162b2 dose 1.

B. Severity of adverse effects from BNT152b2 dose 2.

C. Severity of adverse effects from mRNA 1273 dose 1.

D. Severity of adverse effects from mRNA 1273 dose 2.

E. Severity of adverse effects from Ad26.COVS.S.